Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors

Brigitte C. Widemann

Research output: Contribution to journalArticle

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1). Complete surgical resection is the standard treatment for MPNSTs. Unresectable MPNSTs carry a poor prognosis, and survival appears to be worse in NF1-associated tumors than in sporadic tumors. The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial. With an increasing understanding of the molecular pathogenesis of MPNSTs, clinical trials with targeted agents have become available and have established that histology-specific trials in this rare malignancy are feasible. This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.

Original languageEnglish (US)
Pages (from-to)322-328
Number of pages7
JournalCurrent Oncology Reports
Volume11
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Neurofibromatosis 1
Neurilemmoma
Sarcoma
Neoplasms
Clinical Trials
Histology
Pediatrics
Incidence
Therapeutics
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. / Widemann, Brigitte C.

In: Current Oncology Reports, Vol. 11, No. 4, 2009, p. 322-328.

Research output: Contribution to journalArticle

@article{059c200e90324d79ad6042d50fc4ee69,
title = "Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors",
abstract = "Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8{\%} to 13{\%} in those with neurofibromatosis type 1 (NF1). Complete surgical resection is the standard treatment for MPNSTs. Unresectable MPNSTs carry a poor prognosis, and survival appears to be worse in NF1-associated tumors than in sporadic tumors. The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial. With an increasing understanding of the molecular pathogenesis of MPNSTs, clinical trials with targeted agents have become available and have established that histology-specific trials in this rare malignancy are feasible. This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.",
author = "Widemann, {Brigitte C.}",
year = "2009",
doi = "10.1007/s11912-009-0045-z",
language = "English (US)",
volume = "11",
pages = "322--328",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors

AU - Widemann, Brigitte C.

PY - 2009

Y1 - 2009

N2 - Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1). Complete surgical resection is the standard treatment for MPNSTs. Unresectable MPNSTs carry a poor prognosis, and survival appears to be worse in NF1-associated tumors than in sporadic tumors. The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial. With an increasing understanding of the molecular pathogenesis of MPNSTs, clinical trials with targeted agents have become available and have established that histology-specific trials in this rare malignancy are feasible. This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.

AB - Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1). Complete surgical resection is the standard treatment for MPNSTs. Unresectable MPNSTs carry a poor prognosis, and survival appears to be worse in NF1-associated tumors than in sporadic tumors. The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial. With an increasing understanding of the molecular pathogenesis of MPNSTs, clinical trials with targeted agents have become available and have established that histology-specific trials in this rare malignancy are feasible. This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=67649388216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649388216&partnerID=8YFLogxK

U2 - 10.1007/s11912-009-0045-z

DO - 10.1007/s11912-009-0045-z

M3 - Article

C2 - 19508838

AN - SCOPUS:67649388216

VL - 11

SP - 322

EP - 328

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

ER -